SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HuMAB companies
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (440)10/29/2002 1:21:03 PM
From: Harold Engstrom  Read Replies (2) of 1022
 
To date, we have seen a shortage of capacity for cell culture processes. But, approvals are not coming as quickly as previously expected, so I am not sure the capacity constraint is a real as stated by the industry. I think there are 2 schools of thought - co.'s that want their own capacity and those who are comfortable with contract facilities. Boehringer-Ingelheim, Lonza Biologics, Quintiles, Covance, and others probably have capacity to sell. And there are some companies I have know that have had 3 years of demand in the freezer prior to approval! There are other companies without the capacity to manufacture enough for the marketplace despite agreements with 3rd parties (i.e., Amgen with Enbrel).

I think use of funds to build an ($100MM-$200MM?) expansion without needing it is not a good move (if that is what they are doing.) They would be better off using money than capacity as leverage.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News